Cytochrome P450 2S1 (CYP2S1) is a member of the cytochrome P450 superfamily of enzymes, which are critical for the metabolism of a wide array of xenobiotics and endogenous compounds. CYP2S1, in particular, exhibits a distinct substrate specificity compared to other cytochrome P450 enzymes, with a preference for metabolizing certain xenobiotics, including environmental pollutants and potentially toxic compounds. The enzyme's expression has been observed in various tissues, notably in extrahepatic tissues such as the skin, lung, and esophagus, suggesting a role in the first line of defense against toxicant exposure through the metabolism and detoxification of harmful substances. CYP2S1's activity contributes to the oxidative metabolism of compounds, facilitating their conversion to more water-soluble derivatives that can be more easily excreted from the body. This function is vital for maintaining cellular homeostasis and protecting the body from potentially carcinogenic and toxic substances.
The inhibition of CYP2S1 activity can significantly impact the metabolism of its substrates, potentially leading to the accumulation of toxic compounds and affecting the body's ability to detoxify environmental pollutants. Inhibition can occur through various mechanisms, including the binding of inhibitors to the enzyme's active site, thereby preventing substrate access and catalysis. Such inhibitors may act competitively, occupying the binding site and thus directly blocking substrate interaction, or non-competitively, binding to an allosteric site and inducing conformational changes that reduce the enzyme's catalytic efficiency. Additionally, certain compounds can inhibit CYP2S1 activity indirectly by interfering with its expression or stability, such as through the modulation of gene transcription or by affecting the enzyme's post-translational modifications and degradation. Understanding the mechanisms underlying CYP2S1 inhibition is crucial for evaluating the enzyme's role in xenobiotic metabolism and the potential consequences of its impaired function on the detoxification processes and overall exposure risk to toxic substances.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $62.00 $260.00 | 21 | |
A broad-spectrum antifungal agent that can inhibit cytochrome P450 enzymes, therefore it can reduce the metabolism of substrates by CYP2S1. | ||||||
Miconazole | 22916-47-8 | sc-204806 sc-204806A | 1 g 5 g | $65.00 $157.00 | 2 | |
An antifungal agent that can inhibit various cytochrome P450 isozymes; though not specific, it can alter the metabolic activity of CYP2S1. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $53.00 $84.00 | 14 | |
Another antifungal that inhibits a variety of P450 enzymes and could decrease the activity of CYP2S1 indirectly. | ||||||
Quinidine | 56-54-2 | sc-212614 | 10 g | $102.00 | 3 | |
An antiarrhythmic agent that is known to inhibit several P450 enzymes and could affect CYP2S1's metabolic processes. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $122.00 | 7 | |
An HIV protease inhibitor that strongly inhibits several P450 enzymes, potentially reducing CYP2S1 activity. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
A histamine H2 receptor antagonist that inhibits several P450 enzymes which could lead to reduced CYP2S1 activity. | ||||||
Isoniazid | 54-85-3 | sc-205722 sc-205722A sc-205722B | 5 g 50 g 100 g | $25.00 $99.00 $143.00 | ||
Primarily used for tuberculosis, it's known to inhibit various P450 enzymes, which could impact CYP2S1 activity. | ||||||
Chloramphenicol | 56-75-7 | sc-3594 | 25 g | $53.00 | 10 | |
An antibiotic that has been reported to inhibit cytochrome P450 enzymes, potentially altering the activity of CYP2S1. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $66.00 | 4 | |
A proton pump inhibitor that can inhibit various P450 enzymes, which could decrease the metabolic capacity of CYP2S1. | ||||||
Ticlopidine Hydrochloride | 53885-35-1 | sc-205861 sc-205861A | 1 g 5 g | $31.00 $97.00 | 2 | |
An antiplatelet drug that inhibits various P450 enzymes and could therefore impact CYP2S1 indirectly. | ||||||